None listed
Conditions
Interventions
None listed
Sponsors
Soon Chun Hyang University Hospital Bucheon
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Disease group: The patients who develop AD or MCI before 65 year-old 2) Control 1 (normal control or first degree family member of AD patient ): The normal persons who have normal neuroimaging (on Brain CT or Brain MRI) and cognitive functions or the first degree senior family member of AD patients. 3) Control 2 (sporadic AD senile patients): The patients who develop AD after 65 year-old, but do not have first degree family history of AD. Alzheimer's disease is diagnosed based on the followings, 1) Dementia by DSM-IV 2) Probable AD by NINCDS-ADRDA 3) Slowly progressive cognitive decline, at least for 6 months 4) Presence of one of the followings according to the revised NINCDS-ADRDA criteria ? Atrophy of medial temporal and/or parietal lobe on MRI, ? Hypometabolism in medial temporal and/or parietal lobe on FDG-PET, or increased uptake in the same area on amyloid PET MCI is diagnosed based on the followings, 1) No dementia or normal 2) Memory complaint by subject or study partner 3) Objective cognitive impairment 4) Preserved activities of daily living Normal is diagnosed based on the followings, 1) No dementia or MCI 2) No significant brain atrophy or other abnormalities in CT or MRI
Exclusion criteria
Exclusion criteria: 1) Blindness or hearing loss to be unable to be tested 2)sick-sinus syndrome, a second or third degree atrioventricular block 3)severe pulmonary disease (acute, severe, or unstable asthma, severe COPD) 4)an active gastric ulcer 5)uncontrolled diabetes mellitus 6)severe hepatic, or renal disease 7)uncured malignancy 8)major depressive disorder, psychosis 9)mental retardation 10)a history of encephalitis 11)head trauma with loss of consciousness longer than one hour 12)a brain tumor, a traumatic intracranial hemorrhage or a subarachnoid hemorrhage 13) abnormal TFT 14) a deficiency in vitamin B12 or folate 15) neurosyphilis 16)metabolic encephalopathy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The validity of genetic or protein markers in predicting AD development or its prognosis. | — |
Secondary
| Measure | Time frame |
|---|---|
| The corrrelations with the known risk genes and biomarkers | — |
Countries
Korea, Republic of
Contacts
Public ContactSun Ah Park
Soon Chun Hyang University
Outcome results
None listed